MR. ISAO SAKAMOTO

After working in the Development Division of Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.), Dr. Sakamoto started his career at Linical in July 2005. Following experiences as a project leader on various clinical trials, including trials of drugs for intractable diseases, and as Manager of Clinical Development, in 2010 he began expanding Linical’s oncology business, as the Director of the Oncology Business Unit. In 2014, he secured the contract for Linical’s first Asian clinical trial, and as the Director of the Asian Development Unit, he worked on developing a platform for the company’s current systems for Asian and global trials. Since September 2015 he was appointed as President of Linical USA Inc., also became Director, President & CEO of Linical Accelovance America Inc., an acquired company, in April 2018 and has been committed to stabilizing and expanding the US business. In December 2020, he became Director of Europe Business, and in May 2021, he was appointed as Director & CEO of Linical Europe Holding GmbH. Since Jan 2023 he has served as Director, President & CEO, Linical USA, Inc.